Incyte Corp. Stock
Incyte Corp. Stock
There is an upward development for Incyte Corp. compared to yesterday, with an increase of €0.91 (1.350%).
With 12 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of €110.00 shows a very positive potential of 61.361% compared to the current price of €68.17 for Incyte Corp..
For the coming years our community has positive and negative things to say abot the Incyte Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Customer and product portfolio" there were negative voices in the community.
With 12 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of €110.00 shows a very positive potential of 61.361% compared to the current price of €68.17 for Incyte Corp..
For the coming years our community has positive and negative things to say abot the Incyte Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Customer and product portfolio" there were negative voices in the community.
Pros and Cons of Incyte Corp. in the next few years
Pros
1
Could be worthwhile Investment >10% per year
1
EBIT growth >5% per year expected
1
Revenue growth >5% per year expected
Cons
1
Dependend from some customers or products
Performance of Incyte Corp. vs. its peers
Security | Change (%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Incyte Corp. | 1.350% | 3.191% | -10.236% | -0.030% | -3.997% | -8.738% | 4.102% |
Seagen Inc. | 0.100% | 0.032% | -20.784% | 22.863% | -16.875% | 183.209% | 334.837% |
Exact Sciences | 1.310% | -9.338% | -14.883% | 76.164% | -4.791% | 168.789% | 1601.766% |
Vertex Pharmaceuticals Inc. | 3.180% | 1.022% | -0.459% | -13.900% | -7.036% | 30.076% | 118.209% |
Comments
Sell Incyte Corp.
Buy Incyte Corp.
Sell Incyte Corp.
Other discussions about Incyte Corp. Stock
Trading Incyte Corp.
Trading Incyte Corp.